Equity
Additional Paid-In Capital
Pfizer Additional Paid-In Capital increased by 0.2% to $94.47B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 0.9%, from $93.60B to $94.47B. Over 5 years (FY 2020 to FY 2025), Additional Paid-In Capital shows relatively stable performance with a 1.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ4 2025
How to read this metric
An increase typically signals recent equity financing activities or the issuance of shares for employee compensation.
Detailed definition
Additional paid-in capital represents the amount of capital received from investors in excess of the par value of the is...
Peer comparison
Common in all corporations; levels depend on the history of equity issuance and stock-based compensation.
Metric ID:
additional_paid_in_capitalHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $89.34B | $89.97B | $90.59B | $90.84B | $91.18B | $91.36B | $91.80B | $92.15B | $92.33B | $92.50B | $92.63B | $93.00B | $93.20B | $93.48B | $93.60B | $93.86B | $94.05B | $94.25B | $94.47B |
| QoQ Change | — | +0.7% | +0.7% | +0.3% | +0.4% | +0.2% | +0.5% | +0.4% | +0.2% | +0.2% | +0.1% | +0.4% | +0.2% | +0.3% | +0.1% | +0.3% | +0.2% | +0.2% | +0.2% |
| YoY Change | — | — | — | — | +2.1% | +1.5% | +1.3% | +1.4% | +1.3% | +1.2% | +0.9% | +0.9% | +0.9% | +1.1% | +1.0% | +0.9% | +0.9% | +0.8% | +0.9% |
Range$89.34B – $94.47B
CAGR+1.2%
Avg YoY Growth+1.2%
Median YoY Growth+1.0%
Current Streak18+ quarters growth
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is Pfizer's additional paid-in capital?
- Pfizer (PFE) reported additional paid-in capital of $94.47B in Q4 2025.
- How has Pfizer's additional paid-in capital changed year-over-year?
- Pfizer's additional paid-in capital increased by 0.9% year-over-year, from $93.60B to $94.47B.
- What is the long-term trend for Pfizer's additional paid-in capital?
- Over 5 years (2020 to 2025), Pfizer's additional paid-in capital has grown at a 1.3% compound annual growth rate (CAGR), from $88.67B to $94.47B.
- What does additional paid-in capital mean?
- Capital contributed by shareholders above the nominal par value of the stock.